Oculis’ (OCS) “Buy” Rating Reiterated at Chardan Capital

Oculis (NASDAQ:OCS)‘s stock had its “buy” rating restated by analysts at Chardan Capital in a note issued to investors on Tuesday,Benzinga reports. They presently have a $28.00 target price on the stock. Chardan Capital’s target price indicates a potential upside of 58.64% from the stock’s previous close.

Separately, HC Wainwright restated a “buy” rating and issued a $30.00 price target on shares of Oculis in a report on Monday. Five analysts have rated the stock with a buy rating, According to MarketBeat, the company has a consensus rating of “Buy” and an average target price of $28.80.

Oculis Price Performance

Oculis stock opened at $17.65 on Tuesday. The stock’s 50 day moving average price is $16.33 and its two-hundred day moving average price is $13.79. The stock has a market capitalization of $714.90 million, a price-to-earnings ratio of -9.15 and a beta of -0.33. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.02 and a current ratio of 4.02. Oculis has a 52-week low of $10.50 and a 52-week high of $18.10.

About Oculis

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.